BioAspect Products offers research grade biosimilars - monoclonal antibodies and Fc fusion proteins. The products are manufactured by our trusted supplier and long-term partner Absolute Antibody (UK), using the company's proprietary recombinant platform.
The growing range of research grade biosimilars available from BioAspect Products in North America includes Trastuzumab, Muromonab, Campath-1H, Rituximab, Infliximab, Daclizumab, Basiliximab, Cetuximab, Satumomab, Acritumomab, Abaciximab, Eculizumab, Efalizumab, Clenoliximab, Ruplizumab, Matuzumab, Humicade, Volociximab and Oxelumab.
Browse our CATALOG HERE.
These research grade biosimilars are research tools for the study and evaluation of biological processes without the need to source and purchase costly therapeutic grade biologics – currently the only alternative.
As the products are free of excipients and/or additives found in the therapeutic formulations, our biosimilars require fewer extra controls in an experimental setting.
Absolute Antibody research grade biosimilars can be used as controls:
- To benchmark novel biotherapeutics (biologics) for pre-clinical lead identification.
- For the development of potency assays.